Dr Reddys

The stock gained 9 per cent in two days after the pharma company reported better-than-expected revenue growth in March quarter (Q4FY22).

Dr Reddy's Laboratories is hoping to go to a regulator for its single-dose Sputnik Light jab as booster dose for approvals by June-end or early July, a senior official said

Tech Mahindra and Wipro have tumbled over 30 per cent, while Apollo Hospitals Enterprise and Dr. Reddy's Laboratories have plummeted 22 per cent so far in calendar year 2022 (CY22)

Indian pharmaceutical major Dr. Reddy's Laboratories Ltd said on Wednesday it was focused on employee safety and business continuity in and around Russia

Closing Bell: The frontline S&P BSE Sensex fell 69 points to settle at 57,232 levels while the Nifty50 shut shop at 17,063 down 29 points

Mankind Pharma to take over manufacturing, marketing and distribution of both products in India; entire integration and transition of the brands likely to be completed by March

All the sectoral indices settled in the negative territory today with technology and public sector banks being the worst hit. The IT and PSB indices dropped nearly 3% and 2%, respectively

BPCL, DLF, Dwarikesh Sugar, Exide, GIC Housing, HDIL, HPCL, IOC, Jindal Saw, KEC Intl, KPIT Tech, Krsnaa Diagnostics, SCI, Sun Pharma, Suven Life, Tata Motors and UCO Bank in focus ahead of Q3 results

Near-term outlook and valuation are expected to support the stock price

For the week, the Sensex and the Nifty indices are down 3% each

For rerating, it needs sustained growth in India, recovery in US

The tablet is the generic therapeutic equivalent of Diovan, approved by the US Food and Drug Administration

Prestige BioPharma Ltd announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialisation of Trastuzumab biosimilar

According to the technical analyst from Anand Rathi, most technical indicators are in favour of the bullish bias for these three stocks

Dr Reddy's is in a pact with RDIF to sell 250 million vials of Sputnik V in India.

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

The stock of the pharmaceutical company was trading at its lowest level since April 9, 2021

The drugmakers include Cipla and Dr Reddy's Laboratories

The maximum retail price (MRP) of each sachet has been fixed at Rs 990

Going ahead, Nomura said, markets will focus more on corporate earnings rather than the broad economic growth in India